Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAntineoplastic Drugs

Customer Synthesis high qualtity Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

Customer Synthesis high qualtity Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6

China Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6 supplier
Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6 supplier Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6 supplier

Large Image :  Customer Synthesis high qualtity Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6

Product Details:

Place of Origin: Weifang,China
Brand Name: RuzE
Model Number: TC-5039

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 1kg, 5kg Or as customer request
Delivery Time: 5-10work days
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 125kg/Month
Contact Now
Detailed Product Description
Product Name: CO-1686 Synonyms: Rociletinib(CO1686);2-Propenamide, N-[3-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-;Rociletinib (CO-1686, AVL-301);Co 1686 N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluor
CAS: 1374640-70-6 MF: C27H28F3N7O3
MW: 555.5515296 EINECS: -0

Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6

                                                  

                                                                             Rociletinib(CO1686) 

 

[PRODUCT NAME]:CO-1686

[CATALOG NUMBER]:ZHY-0011

[CAS NUMBER]:1374640-70-6

[MOLECULAR FORMULA]:C27H28F3N7O3

[MOLECULAR WEIGHT]:555.55200

[BATCH NO]:20190225

[TEST]:SPECIFICATION

[APPEARANCE]:White Solid

[ASSAY]: 99%min

[WATER]:0.5%max


Safety Information

Risk Statements 23-25-36
Safety Statements 24
HS Code 29335990

CO-1686 Usage And Synthesis

Anti-cancer drugs On May 20, 2014, Clovis Oncology announced that the US FDA had granted its test drug CO-1686 for breakthrough treatment drug qualification, as a second line, single administrated drug for the treatment of EFGR mutation non-small cell lung cancer (NSCLC) of the T790M mutation patients. The awarding for this breakthrough therapeutic drug eligibility was based on the efficacy and safety results of Co-1686 in an ongoing Phase 1/2 study. Data of related study have shown that CO-1686 is a third-generation EGFR inhibitor, being used for the treatment of non-small cell lung cancer, overcoming the drug resistance generated from the EGFR T790M mutations, and has excellent efficacy and tolerability on NSCLC with T790M + EGFR mutations. Its major market competitor, the third-generation EGFR inhibitor, AZD9291 (AstraZeneca) has also gained FDA's groundbreaking drug eligibility.
CO-1686 is a novel, oral-administrated, targeted covalent (irreversible) inhibitor of the epidermal growth factor receptor (EGFR) mutations, being able to suppress key activation mutations and T790 drug-resistant mutations, leaving the wild-type EGFR signal unused. This drug was developed for the treatment of NSCLC patients carrying initially activated EGFR mutations and major resistant mutant T790M.
The above information is compiled and edited by Xiao Nan of Chemicalbook.
Biological activity Rociletinib (CO-1686, AVL-301) is an irreversible, mutation-selective EGFR inhibitor that targets EGFRL858R/T790M and EGFRWT with a Ki of 21.5 nM and 303.3 nM, respectively. Phase 2.
Target: EGFR (L858R/T790M) EGFR (wt)
IC50: 21.5 nM (Ki) 303.3 nM (Ki)
In vitro study CO-1686 inhibited the p-EGFR in EGFR-expressing cells with an IC50 ranging from 62 to 187 nM while inhibiting EGFR phosphorylation. In three WT EGFR-expressing cells, the IC50 is larger than 2,000 nM. CO-1686 can selectively inhibit the growth of mutant EGFR expressing NSCLC cells with a GI50 ranging from 7 to 32 nM while inducing apoptosis. The CO-1686-resistant NSCLC cell line exhibited a signal for epithelial-mesenchymal transition and increased susceptibility to AKT inhibitors.
In vivo studies In all EGFR mutant models, as well as in transgenic mice expressing human EGFRL858R-and EGFRL858R/T790M, CO-1686 caused significant tumor growth inhibition in a dose-dependent manner.
Synthesis method 5-fluoro-2-nitroanisole was condensed with piperazine, acetylated and reduced to give 1-(3-methoxy-4-aminophenyl)-4-acetylpiperazine (4) In addition, use 2, 4-dichloro-5-trifluoro methyl pyrimidine to undergo condensation with 3-nitroaniline, reduction and amidation to obtain N-[3-(2-Chloro-5-trifluoromethyl-pyrimidin-4-amino) phenyl] acrylamide (7). 4 and 7 were condensed to give the EGFR inhibitor, the anticancer drug CO-1686 with a total yield of about 71% (based on 2, 4-dichloro-5-trifluoromethyl pyrimidine).
Reference: Synthesis of CO-1686 [J]. Chinese Pharmaceutical Industry, 2014, 45 (8): 710-713.
OF: (1) Lai Yisheng, male, professor, doctoral supervisor, engaged in anti-inflammatory and anti-tumor drugs studied. (2) Zhang Shan, female, graduate students, professional direction: medicinal chemistry.

 

Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6

Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6

 

Customer Synthesis high qualtity  Anti-cancer drugs Rociletinib(CO1686) CAS 1374640-70-6

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ruze01

Send your inquiry directly to us (0 / 3000)